FTFinancial Times·1hBusiness
score-0.30
Novartis raises profit outlook despite $1.9bn impairment on rare disease drug
Original
Novartis takes $1.9bn writedown on key drug after blockbuster Avidity acquisition
“Contrasts a significant financial loss and impairment charge with a positive outlook revision, creating a conflicting corporate narrative.”